WHO recommends twice-yearly injectable lenacapavir for HIV prevention

LEN now joins other WHO-recommended PrEP options—such as daily oral PrEP, injectable cabotegravir, and the dapivirine vaginal ring—as part of a growing arsenal of tools to end the HIV epidemic. - Kenya breaking news | Kenya news today | Capitalfm.co.ke..

✨ Key Highlights

The World Health Organization (WHO) has recommended the use of injectable lenacapavir (LEN) twice a year as an innovative pre-exposure prophylaxis (PrEP) for HIV prevention, announced during the 13th International AIDS Society Conference in Kigali, Rwanda.

1.3 million new HIV infections were recorded in 2024, highlighting the need for effective prevention methods.
Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, emphasized that LEN is a transformative option for those at risk.
The guidelines simplify testing protocols, promoting access to long-acting PrEP via community-based delivery.

Continue Reading

Read the complete article from Capital News

📰 Read Full Article

Related News

top2w ago

Kenya picked for early rollout of injectable HIV prevention drug Lenacapavir

Kenya has been chosen as one of nine countries for the early rollout of Lenacapavir, an injectable drug for HIV prevention, approved by the World Health Organization (WHO).

KBC Top Stories

📰 Read Full Story

top2w ago

Kenya to roll out long-acting injectable HIV PrEP Lenacapavir by Jan 2026

Kenya plans to launch the long-acting injectable HIV Pre-Exposure Prophylaxis (PrEP) Lenacapavir by January 2026 after its approval from the World Health Organization.

Capital News

📰 Read Full Story

entertainment2w ago

Beyond Daily Pills- WHO Backs New Long-Acting HIV Prevention Injection

The World Health Organization (WHO) has introduced new guidelines endorsing the use of injectable lenacapavir (LEN) as a pre-exposure prophylaxis (PrEP) option for HIV prevention, aimed at significantly enhancing global efforts against the virus.

Ghafla! (Entertainment)

📰 Read Full Story